Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 43, 2008, Pages 16731-16736

  Sokol, Harry ^a   Pigneur, Bénédicte ^b   Watterlot, Laurie ^a   Lakhdari, Omar ^a   Bermúdez Humarán, Luis G ^a   Gratadoux, Jean Jacques ^a   Blugeon, Sébastien ^a   Bridonneau, Chantal ^a   Furet, Jean Pierre ^a   Corthier, Gérard ^a   Grangette, Corinne ^c   Vasquez, Nadia ^d   Pochart, Philippe ^d   Trugnan, Germain ^b   Thomas, Ginette ^b   Blottière, Hervé M ^a   Doré, Joël ^a   Marteau, Philippe ^e   Seksik, Philippe ^b   Langella, Philippe ^a  

^a CEMAGREF   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Bioinformatique et Chimie Moléculaire   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

IBD; Microbiota; Probiotic

Indexed keywords

2,4,6 TRINITROBENZENESULPHONIC ACID; A 2 165; BENZENE DERIVATIVE; BUTYRIC ACID; COLISTIN; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; PROBIOTIC AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM LONGUM INFANTIS; CELL STIMULATION; CELL STRAIN CACO 2; CLOSTRIDIUM PERFRINGENS; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOSCOPY; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPERIMENTAL MOUSE; FAECALIBACTERIUM PRAUSNITZII; FIRMICUTES; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE BIOPSY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS SALIVARIUS; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RECURRENT DISEASE; REPORTER GENE; SUPERNATANT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; COLITIS; CROHN DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES; MICE; NF-KAPPA B; PROBIOTICS; RUMINOCOCCUS; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); FAECALIBACTERIUM PRAUSNITZII; FIRMICUTES; MUS;

EID: 55949124035     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804812105     Document Type: Article

References (32)

1. Loftus EV, Jr (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126:1504-1517.
2. Seksik P, et al. (2006) Review article: The role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 24:11-18.
3. Rutgeerts P, et al. (1991) Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338:771-774.
4. Darfeuille-Michaud A, et al. (1998) Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115:1405-1413.
5. Sokol H, Lepage P, Seksik P, Dore J, Marteau P (2007) Molecular comparison of dominant microbiota associated with injured versus healthymucosain ulcerative colitis. Gut 56:152-154.
6. Sokol H, et al. (2006) Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 12:106-111.
7. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380-3389.
8. Manichanh C, et al. (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55:205-211.
9. Frank DN, et al. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780-13785.
10. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ (2006) Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12:1136-1145.
11. Marteau P, et al. (2006) Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 55:842-847.
12. Daniel C, et al. (2006) Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl Environ Microbiol 72:5799-5805.
13. Segain JP, et al. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn's disease. Gut 47:397-403.
14. Mayr-Harting A, Hedges AJ, Berkeley RCW (1972) Methods for studying bacteriocins. Methods Microbiol 7A:315-422.
15. Dabard J, et al. (2001) Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces. Appl Environ Microbiol 67:4111-4118.
16. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229-241.
17. Kelly D, et al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5:104-112.
18. Barcenilla A, et al. (2000) Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66:1654-1661.
19. Suau A, et al. (1999) Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within thehumangut. Appl Environ Microbiol 65:4799-4807.
20. Wehkamp J, et al. (2004) NOD2 (CARD 15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53:1658-1664.
21. Wehkamp J, et al. (2005) Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 102:18129-18134.
22. Wehkamp J, et al. (2004) NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infect Immun 72:5750-5758.
23. Nenci A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:557-561.
24. Foligné B, Grangette C, Pot B (2005) Probiotics in IBD: Mucosal and systemic routes of administration may promote similar effects. Gut 54:727-728.
25. Rachmilewitz D, et al. (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520-528.
26. Sheil B, et al. (2004) Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53:694-700.
27. Vasquez N, et al. (2007) Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: A study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm Bowel Dis 13:684-692.
28. Lan A, et al. (2007) Survival and metabolic activity of selected strains of Propionibacterium freudenreichii in the gastrointestinal tract of human microbiota-associated rats. Br J Nutr 97:714-724.
29. Foligne B, et al. (2007) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13:236-243.
30. Foligne B, et al. (2006) Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig Dis Sci 51:390-400.
31. Wallace JL, MacNaughton WK, Morris GP, Beck PL (1989) Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29-36.
32. Ameho CK, et al. (1997) Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41:487-493.